PreMD's appeal to FDA over cholesterol test fails
This article was originally published in Clinica
Executive Summary
The appeal launched by predictive medicine company PreMD against the not substantially equivalent (NSE) letter it received from the US FDA for Prevu(x), its skin cholesterol test, has failed.